Jpmorgan Chase & CO Anebulo Pharmaceuticals, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ANEB
# of Institutions
14Shares Held
7.34MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA5.37MShares$7.51 Million11.7% of portfolio
-
Lvw Advisors, LLC641KShares$897,4540.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT511KShares$715,5020.06% of portfolio
-
Morgan Stanley New York, NY399KShares$558,9060.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX158KShares$221,0060.05% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $35.9M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...